Drug Profile


Alternative Names: JNJ-26481585

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Pharmaceutica; Janssen Research & Development; NewVac
  • Class Antineoplastics; Hydroxy acids; Hydroxylamines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cutaneous T cell lymphoma; Leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 03 Jan 2017 NewVac plans a phase III trial for Ovarian cancer
  • 15 Dec 2016 Biomarkers information updated
  • 08 Nov 2016 Phase-II clinical trials in Ovarian cancer (Second-line therapy or greater, Combination therapy, Metastatic disease) in Russia (PO) (NCT02948075)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top